SAGE Therapeutics (SAGE) Misses Q3 EPS by 36c, Reports $1.8B of Cash on Hand

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.21), $0.36 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $1.96 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air Lines stock climbs on earnings beat and strong guidance
• Benchmark Reiterates Buy Rating on Penske Automotive Group (PAG)